Literature DB >> 28646995

Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Markus Ketteler1, Geoffrey A Block2, Pieter Evenepoel3, Masafumi Fukagawa4, Charles A Herzog5, Linda McCann6, Sharon M Moe7, Rukshana Shroff8, Marcello A Tonelli9, Nigel D Toussaint10, Marc G Vervloet11, Mary B Leonard12.   

Abstract

The KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of CKD-MBD represents a selective update of the prior CKD-MBD Guideline published in 2009. This update, along with the 2009 publication, is intended to assist the practitioner caring for adults and children with chronic kidney disease (CKD), those on chronic dialysis therapy, or individuals with a kidney transplant. This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document. Topic areas encompassing updated recommendations include diagnosis of bone abnormalities in CKD-mineral and bone disorder (MBD), treatment of CKD-MBD by targeting phosphate lowering and calcium maintenance, treatment of abnormalities in parathyroid hormone in CKD-MBD, treatment of bone abnormalities by antiresorptives and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease.
Copyright © 2017 KDIGO. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  KDIGO CKD-MBD Guideline; bone mineral density; calcium; dialysis; hyperparathyroidism; hyperphosphatemia; kidney transplantation

Mesh:

Substances:

Year:  2017        PMID: 28646995     DOI: 10.1016/j.kint.2017.04.006

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  243 in total

1.  Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study.

Authors:  Rabi Yacoub; Girish N Nadkarni; Daniel I McSkimming; Lee D Chaves; Sham Abyad; Mark A Bryniarski; Amanda M Honan; Shruthi A Thomas; Madan Gowda; John C He; Jaime Uribarri
Journal:  Exp Biol Med (Maywood)       Date:  2018-12-12

2.  Chronic kidney disease following twin-to-twin transfusion syndrome-long-term outcomes.

Authors:  Nabil Ziad Melhem; Sarah Ledermann; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2018-12-17       Impact factor: 3.714

3.  What Is the Role of Vitamin D Supplementation on Vascular Health in CKD?

Authors:  Nigel D Toussaint; Irene Ruderman
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-07       Impact factor: 8.237

Review 4.  CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.

Authors:  Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 5.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

6.  Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing.

Authors:  Elizabeth A Swallow; Mohammad W Aref; Corinne E Metzger; Spencer Sacks; Demi R Lehmkuhler; Neal Chen; Max A Hammond; Paul R Territo; Thomas L Nickolas; Sharon M Moe; Matthew R Allen
Journal:  Bone       Date:  2019-07-09       Impact factor: 4.398

7.  Skeletal accumulation of fluorescently tagged zoledronate is higher in animals with early stage chronic kidney disease.

Authors:  E A Swallow; M W Aref; N Chen; I Byiringiro; M A Hammond; B P McCarthy; P R Territo; M M Kamocka; S Winfree; K W Dunn; S M Moe; M R Allen
Journal:  Osteoporos Int       Date:  2018-06-11       Impact factor: 4.507

Review 8.  Updates in CKD-Associated Osteoporosis.

Authors:  Pascale Khairallah; Thomas L Nickolas
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 9.  The use of bone mineral density measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed microtomography in chronic kidney disease.

Authors:  Martin Jannot; Fabrice Mac-Way; Vanessa Lapierre; Marie-Helene Lafage-Proust
Journal:  J Nephrol       Date:  2017-09-12       Impact factor: 3.902

Review 10.  Chronic Kidney Disease-Mineral and Bone Disorders: Pathogenesis and Management.

Authors:  Jorge B Cannata-Andía; Beatriz Martín-Carro; Julia Martín-Vírgala; Javier Rodríguez-Carrio; José Joaquín Bande-Fernández; Cristina Alonso-Montes; Natalia Carrillo-López
Journal:  Calcif Tissue Int       Date:  2020-11-15       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.